Identification of a Novel Pathogenic Germline KDR Variant in Melanoma

Clinical Cancer Research

Volumn 22, Issue 10, 2016, Pages 2377-2385

  Silva, Ines P ^a,b   Salhi, Amel ^a,b   Giles, Keith M ^a,b   Vogelsang, Matjaz ^b,c   Han, SungW ^b,d   Ismaili, Naima ^e   Lui, Kevin P ^a,b   Robinson, Eric M ^a,b   Wilson, Melissa A ^b   Shapiro, Richard L ^b,e   Pavlick, Anna ^b,e   Zhong, Judy ^b,d   Kirchhoff, Tomas ^b,c   Osman, Iman ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c Departmentof Population Health and Environmental Medicine   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e Department of Pathology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; GENOMIC DNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; KDR PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; ARTICLE; CANCER PROGNOSIS; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENOTYPE; GERM LINE; HUMAN; HUMAN CELL; MALE; MELANOMA; MELANOMA CELL LINE; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PHENOTYPE; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR INVASION; TUMOR VASCULARIZATION; WILD TYPE; GENETIC VARIATION; GENETICS; GERM CELL; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; FEMALE; GENETIC VARIATION; GERM CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84968830552     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1811     Document Type: Article

References (50)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
2. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
3. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65.
5. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:782-9.
6. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-23.
7. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46.
8. Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, et al. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res 2014;20:3328-37.
9. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
10. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012;44:133-9.
11. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014;20:682-8.
12. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014;19: 616-22.
13. Shitara M, Okuda K, Suzuki A, Tatematsu T, Hikosaka Y, Moriyama S, et al. Genetic profiling of thymic carcinoma using targeted next-generation sequencing. Lung Cancer 2014;86:174-9.
14. Xu Z, Huo X, Ye H, Tang C, Nandakumar V, Lou F, et al. Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform. PLoS One 2014;9:e100442.
15. Redig AJ, Janne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015;33:975-7.
16. Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, et al. Actionable exomic incidental findings in 6503 participants: Challenges of variant classification. Genome Res 2015;25:305-15.
17. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Translat Med 2015;7:283ra53.
18. Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.
19. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22: 3053-62.
20. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 2011;43:1108-13.
21. Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, Stark M, et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet 2011;43:1114-8.
22. Rendleman J, Shang S, Dominianni C, Shields JF, Scanlon P, Adaniel C, et al. Melanoma risk loci as determinants of melanoma recurrence and survival. J Translat Med 2013;11:279.
23. Rendleman J, Vogelsang M, Bapodra A, Adaniel C, Silva I, Moogk D, et al. Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. J Med Genet 2015;52:231-9.
24. de Miera EV, Friedman EB, Greenwald HS, Perle MA, Osman I. Development of five new melanoma low passage cell lines representing the clinical and genetic profile of their tumors of origin. Pigment Cell Melanoma Res 2012;25:395-7.
25. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
26. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
27. Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, et al. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer 2013;13:169.
28. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: Detection of BRAF- and c-kit-activating mutations by highresolution amplicon melting analysis. Hum Pathol 2005;36:486-93.
29. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 2011;17:5257-67.
30. Dong G, Guo X, Fu X, Wan S, Zhou F, Myers RE, et al. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer. Cancer Sci 2012;103:561-8.
31. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262-9.
32. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 2011;71:5512-21.
33. Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, et al. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumour Biol 2014;35: 11473-81.
34. Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005;4:220-6.
35. Adamcic U, Skowronski K, Peters C, Morrison J, Coomber BL. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia 2012;14:612-23.
36. Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 2013;123:1732-40.
37. Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PloS one 2011;6:e25264.
38. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011;10:558-65.
39. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
40. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-74.
41. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 2013;493:216-20.
42. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012;337:64-9.
43. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42:410-4.
44. Moes-Sosnowska J, Szafron L, Nowakowska D, Dansonka-Mieszkowska A, Budzilowska A, Konopka B, et al. Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type. Orphanet J Rare Dis 2015;10:32.
45. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
46. Hansen TF, Sorensen FB, Spindler KL, Olsen DA, Andersen RF, Lindebjerg J, et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010;456:251-60.
47. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19:5598-605.
48. Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol 2014;15:620-30.
49. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2:632-42.
50. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012;30:34-41.